Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant.

Alsaleh, Khalid; Mohamed El Zawahry, Heba; Bounedjar, Adda; Oukkal, Mohammed; Saadeddin, Ahmed; Mahfouf, Hassen; Kamel, Bouzid; Bensalem, A.; Abdel‐Razeq, Hikmat; Kandil, Alaa; Abulkhair, Omalkhair; Owaish Al-Foheidi, Meteb; Ghosn, Marwan; Boussen, Hamouda; Haddaoui, Abderrazak; Ayari, J.; Alghamdi, Mohammed; A. Abdulaziz, Nashwa; Kullab, Sharif; A. Nabholtz, Jean-Marc

doi:10.1200/jco.2022.40.16_suppl.596

Public

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant.

Shared by NobleBlocks on Jun 1, 2022 • 12:00 AM UTC

Authors:

Khalid Alsaleh

Heba Mohamed El Zawahry

Adda Bounedjar

Abstract

596 Background: Luminal, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) encompasses the most common subtype of breast malignancies. Neoadjuvant strategies of operable BC are primarily based upon chemotherapy (CT), while neoadjuvant hormone therapy (NAHT) has not been wel...

Subject

Palbociclib

Medicine

Fulvestrant

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!